Literature DB >> 31671209

Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study.

Yan Wu1, Yu Wang2, Lijun Wang3, Peng Yin3, Yun Lin2, Maigeng Zhou3.   

Abstract

Melanoma is an aggressive form of skin cancer, and a worldwide problem with increasing incidence. Little is known about the burden of melanoma in the Chinese population. We evaluated temporal trends and geographic variation in melanoma-associated burden, to narrow an important knowledge gap concerning the consequences of this disorder across time, provinces in China. After the general analytic strategy used in the 2017 Global Burden of Disease study, we analyzed the incidence, mortality, prevalence and disability-adjusted life-years (DALYs) of melanoma, by age, sex and geography from 1990 to 2017. Levels in melanoma burden were assessed for 33 province-level administrative units between 1990 and 2017. We used joinpoint regression analysis to estimate the slope of incidence and mortality trends. The age-standardized incidence rate of melanoma was 0.9 per 100,000 in 2017, with a 110.3% rise compared to 1990. Although the age-standardized DALYs rate (per 100,000) decreased from 9.1 in 1990 to 7.6 in 2017, it showed an upward trend from 2007 to 2017. The DALYs rate increased steadily with age for females while increased and peaked at 55-59 years for males. The incidence of melanoma was higher in the clustered eastern provinces than western provinces, while the DALYs showed a pattern in opposite direction. In China, there has been a substantial increase in the burden of melanoma over the last decade, representing an ongoing challenge in Chinese population. More targeted strategies should be developed for elderly population, especially for females, to reduce the melanoma burden throughout China, particularly the western provinces.
© 2019 UICC.

Entities:  

Keywords:  burden of disease; disability-adjusted life-years; epidemiology; melanoma; public health

Year:  2019        PMID: 31671209     DOI: 10.1002/ijc.32764

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression.

Authors:  Xuerui Wu; Yu Wang; Chen Chen; Yadong Xue; Shuyun Zheng; Limin Cai
Journal:  Genet Res (Camb)       Date:  2022-07-07       Impact factor: 1.375

2.  Lycorine hydrochloride inhibits melanoma cell proliferation, migration and invasion via down-regulating p21Cip1/WAF1.

Authors:  Shaomin Shi; Chongyang Li; Yanli Zhang; Chaowei Deng; Mengqin Tan; Guangzhao Pan; Juan Du; Yacong Ji; Qian Li; Hanghua Liang; Wei Liu; Leiyang Guo; Gaichao Zhao; Yaling Liu; Hongjuan Cui
Journal:  Am J Cancer Res       Date:  2021-04-15       Impact factor: 5.942

3.  Environmental effects of stratospheric ozone depletion, UV radiation, and interactions with climate change: UNEP Environmental Effects Assessment Panel, Update 2020.

Authors:  R E Neale; P W Barnes; T M Robson; P J Neale; C E Williamson; R G Zepp; S R Wilson; S Madronich; A L Andrady; A M Heikkilä; G H Bernhard; A F Bais; P J Aucamp; A T Banaszak; J F Bornman; L S Bruckman; S N Byrne; B Foereid; D-P Häder; L M Hollestein; W-C Hou; S Hylander; M A K Jansen; A R Klekociuk; J B Liley; J Longstreth; R M Lucas; J Martinez-Abaigar; K McNeill; C M Olsen; K K Pandey; L E Rhodes; S A Robinson; K C Rose; T Schikowski; K R Solomon; B Sulzberger; J E Ukpebor; Q-W Wang; S-Å Wängberg; C C White; S Yazar; A R Young; P J Young; L Zhu; M Zhu
Journal:  Photochem Photobiol Sci       Date:  2021-01-20       Impact factor: 4.328

4.  Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis.

Authors:  Shuang Wu; Chuanping Yuan; Lei Chen; Lanlan Guo; Yong Chen; Zhenwei Peng; Lixia Lu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

5.  PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.

Authors:  Gang Yang; Shuya Liu; Mazaher Maghsoudloo; Marzieh Dehghan Shasaltaneh; Parham Jabbarzadeh Kaboli; Cuiwei Zhang; Youcai Deng; Hajar Heidari; Maliheh Entezari; ShaoZhi Fu; QingLian Wen; Saber Imani
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

6.  Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial.

Authors:  Lili Mao; Ya Ding; Xue Bai; Xinan Sheng; Jie Dai; Zhihong Chi; Chuanliang Cui; Yan Kong; Yun Fan; Yanjun Xu; Xuan Wang; Bixia Tang; Bin Lian; Xieqiao Yan; Siming Li; Li Zhou; Xiaoting Wei; Caili Li; Jun Guo; Xiaoshi Zhang; Lu Si
Journal:  Front Oncol       Date:  2021-08-24       Impact factor: 6.244

7.  lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR‑424‑5p/LATS1 axis.

Authors:  Xuemei Han; Yuxi Jia; Xiangru Chen; Chengkuan Sun; Jing Sun
Journal:  Oncol Rep       Date:  2021-09-20       Impact factor: 3.906

8.  YY1-induced long non-coding RNA small nucleolar RNA host gene 8 promotes the tumorigenesis of melanoma via the microRNA-656-3p/SERPINE1 mRNA binding protein 1 axis.

Authors:  Baihui Shan; Shengming Qu; Sha Lv; Dandan Fan; Shu Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

9.  OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.

Authors:  ChuanLiang Cui; Xuan Wang; Bin Lian; Qing Ji; Li Zhou; Zhihong Chi; Lu Si; Xinan Sheng; Yan Kong; Jiayi Yu; Siming Li; Lili Mao; Bixia Tang; Jie Dai; Xieqiao Yan; Xue Bai; Robert Andtbacka; Jun Guo
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

Review 10.  Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.

Authors:  Lili Mao; Zhonghui Qi; Li Zhang; Jun Guo; Lu Si
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.